In 2015, CHAI began partnering with the American Cancer Society (ACS) to increase access to high-quality and affordable treatment, strengthen health worker capacity, and help governments establish plans to comprehensively manage the disease. In 2017, CHAI and ACS announced a groundbreaking agreement with pharmaceutical manufacturers, which was then expanded in 2020. With individual agreements with Mylan, Novartis, and Pfizer, Inc., the Cancer Access Partnership increases access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. The agreements will result in significant savings on high-quality medicines, including chemotherapy regimens for the three cancers that cause the most deaths in Africa-- breast, cervical, and prostate. Learn more about the partnership
here.